The Effects of Tildrakizumab in the Epigenetic Aging Deviation of Psoriasis: A 52-Week Open-Label Study.

Ilumya (tildrakizumab-asmn) - Sun Pharma, Almirall

http://www.ncbi.nlm.nih.gov/pubmed/42617697

Abrar Qureshi; Betul Macit; Carlos G Wambier; Chelsie E Benca-Bachman; Eunyoung Cho; John E McGeary; Lucas Paulo de Lima Camillo

Aug 20, 2026